menu
    • menu
    [{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Huyabio International AND Tianjin Institute of Pharmaceutical Research Joint Venture Submits Chinese NDA for Efinaconazole as Jublia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Efinaconazole","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim ImmunoTech \/ Not Applicable"},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Announces its Joint Venture Aleor Dermaceuticals Receives USFDA Tentative Approval for Efinaconazole Topical Solution, 10%","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Efinaconazole","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aleor Dermaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical solution","sponsorNew":"Aleor Dermaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aleor Dermaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for JUBLIA

    Menu

    JUBLIA

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aleor Dermaceuticals

                            India arrow
                            FNCE 2024
                            Not Confirmed

                            Aleor Dermaceuticals

                            India arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efinaconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alembic Announces its Joint Venture Aleor Dermaceuticals Receives USFDA Tentative Approval for Efinaconazole T...

                            Details : Efinaconazole Topical Solution, 10% is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 08, 2021

                            Lead Product(s) : Efinaconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aim ImmunoTech

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            Aim ImmunoTech

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efinaconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Huyabio International AND Tianjin Institute of Pharmaceutical Research Joint Venture Submits Chinese NDA for E...

                            Details : Jublia is the first triazole-based topical formulation approved for the treatment of onychomycosis, a common and destructive fungal infection of the toenails.

                            Brand Name : Jublia

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 09, 2021

                            Lead Product(s) : Efinaconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            Close
                            4